Milan, Italy

Alessia Montagnoli

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2007-2015

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Alessia Montagnoli: Innovator in Therapeutic Combinations and PARP-1 Inhibitors

Introduction

Alessia Montagnoli is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic combinations and inhibitors. With a total of four patents to her name, Montagnoli's work is paving the way for advancements in cancer treatment and other medical applications.

Latest Patents

Montagnoli's latest patents include a therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent. This invention provides a novel therapeutic approach by combining specific compounds to enhance treatment efficacy. Another notable patent involves isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors. These compounds selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1, offering potential treatments for various diseases, including cancer and cardiovascular conditions.

Career Highlights

Throughout her career, Alessia Montagnoli has worked with esteemed companies such as Nerviano Medical Sciences S.r.l. and Pfizer Italia S.r.l. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to the advancement of medical science.

Collaborations

Montagnoli has collaborated with notable colleagues, including Paolo Orsini, Gianluca Mariano, and Enrico Papeo. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceuticals.

Conclusion

Alessia Montagnoli's contributions to the field of medicine through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to inspire advancements in therapeutic treatments and medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…